scholarly journals Association of plasma leptin, pro‐inflammatory adipokines and cancer‐related fatigue in early‐stage breast cancer patients: A prospective cohort study

2019 ◽  
Vol 23 (6) ◽  
pp. 4281-4289 ◽  
Author(s):  
Yi Long Toh ◽  
Chia Jie Tan ◽  
Angie Hui Ling Yeo ◽  
Maung Shwe ◽  
Han Kiat Ho ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Cancer Related Fatigue ◽  
Plasma Leptin

Mitochondrial DNA content in peripheral blood as a biomarker for cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 10018-10018 ◽  
Author(s):  
Jung-Woo Chae ◽  
Peh Siang Chua ◽  
Terence NG ◽  
Hui Ling Angie Yeo ◽  
Maung Shwe ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mitochondrial Dna ◽  
Cohort Study ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Prospective Cohort ◽  
Early Stage ◽  
Breast Cancer Patients ◽  
Time Points ◽  
Cancer Related Fatigue

10018 Background: Cancer-related fatigue (CRF) is reported to be associated with mitochondrial dysfunction. Hence, mitochondrial DNA (mtDNA) content, a biomarker of mitochondrial dysfunction, is hypothesized to correlate with the onset of CRF. This study aimed to evaluate the association between peripheral blood mtDNA content and CRF in patients receiving chemotherapy. Methods: This was a prospective cohort study. Early-stage breast cancer patients (Stages I to III) receiving anthracycline or taxane-based chemotherapy were recruited. CRF was assessed using the validated Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) at two time points: baseline (T1; prior to treatment) and 6 weeks after initiation of treatment (T2). Worsening of CRF was defined as ≥10% increase in the overall MFSI-SF score at T2. Peripheral blood mtDNA content was measured at both time points using real-time quantitative polymerase chain reaction. Multiple logistic regression was utilized to evaluate the association between mtDNA reduction and worsening of CRF, adjusting for age, anxiety, insomnia and other clinically important covariates. Results: A total of 91 patients [mean age (±SD): 51.3 (9.2) years; 81.3% Chinese; 63.3% receiving anthracycline-based chemotherapy] were recruited. Proportions of patients with worsening of CRF increased from the lower to the upper quartiles of mtDNA reduction (26.1%, 30.4%, 52.2%, and 59.1% in quartiles 1, 2, 3, and 4, respectively, P = 0.010 for trend). Reduction of mtDNA content was significantly greater among those with worsening of CRF compared to those without CRF [mean reduction (±SD): 16.3 (23.5) vs 6.0 (17.3), P = 0.018]. After adjusting for covariates, every 1-unit reduction of the mtDNA content was associated with a 4% increase risk for worsening of CRF (95% CI, 1%-8%; P = 0.016). Conclusions: This is the first study to show that reduction of mtDNA content in peripheral blood is associated with onset of CRF in patients receiving chemotherapy. Further validation studies are required to confirm the findings.

scholarly journals Analysis of Undesirable Sequelae of Sentinel Node Surgery in Breast Cancer Patients – a Prospective Cohort Study

2017 ◽  
Vol 24 (4) ◽  
pp. 891-897
Author(s):  
Dominika Kozak ◽  
Iwona Głowacka-Mrotek ◽  
Tomasz Nowikiewicz ◽  
Zygmunt Siedlecki ◽  
Wojciech Hagner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Sentinel Node ◽  
Cancer Patients ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Breast Cancer Patients

Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients? A prospective cohort study

2015 ◽  
Vol 210 (5) ◽  
pp. 886-890 ◽  
Author(s):  
Anees B. Chagpar ◽  
Meghan Butler ◽  
Brigid K. Killelea ◽  
Nina R. Horowitz ◽  
Karen Stavris ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Three Dimensional ◽  
Breast Cancer Patients

scholarly journals HIV infection in breast cancer patients from Mozambique: A prospective cohort study

2019 ◽  
Vol 30 ◽  
pp. iii69
Author(s):  
M.D.R.A. Brandão ◽  
A. Guisseve ◽  
G. Bata ◽  
G. de Morais ◽  
M. Alberto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Hiv Infection ◽  
Cancer Patients ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Breast Cancer Patients

UNICANCER: Prospective cohort study of treatment related chronic toxicities in patients with localized breast cancer (CANTO).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. TPS10125-TPS10125
Author(s):  
Ines Maria Vaz Duarte Luis ◽  
Paul H. Cottu ◽  
Christel Mesleard ◽  
Anne-Laure Martin ◽  
Agnes Dumas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Treatment Completion ◽  
Breast Cancer Patients ◽  
European Organization ◽  
Patient Reported

TPS10125 Background: Corresponding with improved survival among breast cancer patients an awareness of the long term effects of cancer treatments has increased. There is now a call for better coordination of care and management of these patients to focus on their survivorship. This study will identify factors associated with the development and persistence of long term toxicities in patients treated for Stage I-III breast cancer. In addition, it will characterize their incidence as well as, psychological, social and economic impacts. Methods: This is a prospective cohort study enrolling newly diagnosed invasive cT0-cT3, cN0-3, M0 breast cancer patients of 26 French comprehensive cancer centers. All patients will be followed for a minimum of 5 years. Patients will be assessed at diagnosis, 3-6 (M0), 12 (M12), 36 (M36), 48 (M48), 60 (M60), months after treatment completion. Treatment completion is defined as completion of primary surgery, chemotherapy or radiotherapy, whichever comes last. Adjuvant trastuzumab, endocrine therapy or participation in clinical trials can be ongoing. CANTO collects an extensive list of clinical, treatment, and toxicity data including validated patient reported outcomes questionnaires ( Hospital Anxiety and Depression scale [HADS], Scheier et Carver’s Questionnaire, Life Orientation Test-Revised [LOT-R], Beck Depression Inventory [BDI-SF], European Organization for Research and Treatment-QOL questionnaire for breast cancer [EORTC QLQC30-BR23], EORTC-FA13, 12 Item Short Form Survey [SF12], Global physical activity questionnaire [GPAQ]6, impact of cancer questionnaire [IOCv2], economic and social questionnaires). Blood collection is available for all patients at diagnosis, M0, M12, M36 and M60. Genotyping will be performed in all samples. Biologic substudies are ongoing (e.g, microbiotic and cognitive substudy). CANTO aggregates a multidisciplinary team of French investigators and created a dedicated national network. Enrolment started in 2012 and by December 2016, 10030 patients were already enrolled, with a goal of 12.000 patients. Clinical trial information: NCT01993498.

Sign in / Sign up

Export Citation Format

Share Document